Concepedia

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

Johanna C. Bendell, David S. Hong, Howard A. Burris, Aung Naing, Suzanne F. Jones, Gerald S. Falchook, Patricia Bricmont, Agnes Elekes, Edwin P. Rock, Razelle Kurzrock

Cancer Chemotherapy and Pharmacology · 2014 · 111 citations · 8 references

DOI

Concepts

References

8

DECLARATION OF HELSINKI.

Bryan Gandevia, Ann Tovell · PubMed · 1964 · 2.1K citations

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

, , +12

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · New England Journal of Medicine · 2012 · 1.8K citations · Full text

, , +10

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa et al. · New England Journal of Medicine · 2010 · 1.2K citations · Full text

, , +13

Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC

Diego F. Calvisi, Sara Ladu, Alexis Gorden et al. · Gastroenterology · 2006 · 728 citations

, , +12